The biopharma landscape in the Asia-Pacific (APAC) region is undergoing significant transformation as China emerges as a powerful player in the industry. Ian Haydock, Editor-In-Chief, Insights, Asia-Pacific at Citeline, will examine the far-reaching implications of China’s growing influence on the region’s outsourcing, manufacturing, and R&D strategies during his keynote speech at CPHI Japan 2023, held from April 19-21.
China’s burgeoning biopharma sector is reshaping its approach to global R&D, with a focus on Southeast Asia and Japan as larger priorities due to recent setbacks in the US. The country now accounts for 24% of global R&D in new drugs and vaccines, compared to 51% for the US. Therapeutic categories such as oncology, rare diseases, and neurology dominate the field.
The shifting dynamics of global biopharma innovation are paving the way for new distribution and regional manufacturing hubs. In Japan, innovation remains strong, although growth has been relatively stable. Drug pricing systems in the country pose challenges for research-based multinationals.
The APAC region’s biopharma innovation is characterized by a diverse group of smaller innovators with fewer products, resulting in a more dynamic supply side that includes a wide array of supply partners. This year’s CPHI Japan is expected to attract 7,000 executives from 95 countries, reflecting a return to its pre-pandemic status.
Jenny Leung, Regional Manager, Informa Markets, emphasizes the growing interest from international audiences in entering the Japanese market and collaborating with regional suppliers, distributors, and manufacturers. The rising competition for partners and supply chain resources has led to Japanese companies being approached earlier than before by potential partners.
In celebration of its 20th anniversary, CPHI Japan 2023 will host special events, including an award ceremony honoring companies that have played a vital role in building Japan’s pharma industry.
